학술논문

Two phase I, pharmacokinetic, and pharmacodynamic studies of DFP-10917, a novel nucleoside analog with 14-day and 7-day continuous infusion schedules.
Document Type
Article
Source
Investigational New Drugs; Feb2019, Vol. 37 Issue 1, p76-86, 11p
Subject
AGAR
BALDNESS
CELL lines
CLINICAL trials
DIARRHEA
DNA
DRUG tolerance
DRUG dosage
CLINICAL drug trials
DRUG toxicity
ELECTROPHORESIS
FEBRILE neutropenia
NEUTROPENIA
THROMBOCYTOPENIA
TUMORS
TREATMENT effectiveness
DEOXYCYTIDINE
PHARMACODYNAMICS
THERAPEUTICS
Language
ISSN
01676997
Abstract
Copyright of Investigational New Drugs is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)